Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 91

1.

Biological mediators of effect of diet and stress reduction on prostate cancer.

Saxe GA, Major JM, Westerberg L, Khandrika S, Downs TM.

Integr Cancer Ther. 2008 Sep;7(3):130-8. doi: 10.1177/1534735408322849.

2.

Adoption of a plant-based diet by patients with recurrent prostate cancer.

Nguyen JY, Major JM, Knott CJ, Freeman KM, Downs TM, Saxe GA.

Integr Cancer Ther. 2006 Sep;5(3):214-23.

PMID:
16880426
3.

Potential attenuation of disease progression in recurrent prostate cancer with plant-based diet and stress reduction.

Saxe GA, Major JM, Nguyen JY, Freeman KM, Downs TM, Salem CE.

Integr Cancer Ther. 2006 Sep;5(3):206-13.

PMID:
16880425
4.

Can diet in conjunction with stress reduction affect the rate of increase in prostate specific antigen after biochemical recurrence of prostate cancer?

Saxe GA, Hébert JR, Carmody JF, Kabat-Zinn J, Rosenzweig PH, Jarzobski D, Reed GW, Blute RD.

J Urol. 2001 Dec;166(6):2202-7.

PMID:
11696736
5.

Effects of a diet rich in phytoestrogens on prostate-specific antigen and sex hormones in men diagnosed with prostate cancer.

Dalais FS, Meliala A, Wattanapenpaiboon N, Frydenberg M, Suter DA, Thomson WK, Wahlqvist ML.

Urology. 2004 Sep;64(3):510-5.

PMID:
15351581
6.

A dietary intervention for recurrent prostate cancer after definitive primary treatment: results of a randomized pilot trial.

Carmody J, Olendzki B, Reed G, Andersen V, Rosenzweig P.

Urology. 2008 Dec;72(6):1324-8. doi: 10.1016/j.urology.2008.01.015. Epub 2008 Apr 8.

PMID:
18400281
7.

Increase of serum prostatic specific antigen and clinical progression in pN + MO prostate cancer.

Josefsen D, Waehre H, Paus E, Fosså SD.

Br J Urol. 1995 Apr;75(4):502-6.

PMID:
7540482
8.

Effects of diet and exercise on insulin, sex hormone-binding globulin, and prostate-specific antigen.

Tymchuk CN, Tessler SB, Aronson WJ, Barnard RJ.

Nutr Cancer. 1998;31(2):127-31.

PMID:
9770724
9.

Minimal effect of a low-fat/high soy diet for asymptomatic, hormonally naive prostate cancer patients.

Spentzos D, Mantzoros C, Regan MM, Morrissey ME, Duggan S, Flickner-Garvey S, McCormick H, DeWolf W, Balk S, Bubley GJ.

Clin Cancer Res. 2003 Aug 15;9(9):3282-7.

10.

Intermediate end point for prostate cancer-specific mortality following salvage hormonal therapy for prostate-specific antigen failure.

D'Amico AV, Moul JW, Carroll PR, Cote K, Sun L, Lubeck D, Renshaw AA, Loffredo M, Chen MH.

J Natl Cancer Inst. 2004 Apr 7;96(7):509-15.

PMID:
15069112
11.

Effect of a 2-year home-based endurance training intervention on physiological function and PSA doubling time in prostate cancer patients.

Hvid T, Lindegaard B, Winding K, Iversen P, Brasso K, Solomon TP, Pedersen BK, Hojman P.

Cancer Causes Control. 2016 Feb;27(2):165-74. doi: 10.1007/s10552-015-0694-1. Epub 2015 Nov 16.

PMID:
26573844
12.
13.
14.

Effects of a genistein-rich extract on PSA levels in men with a history of prostate cancer.

deVere White RW, Hackman RM, Soares SE, Beckett LA, Li Y, Sun B.

Urology. 2004 Feb;63(2):259-63.

PMID:
14972467
15.

Sex steroid hormones and the androgen receptor gene CAG repeat and subsequent risk of prostate cancer in the prostate-specific antigen era.

Platz EA, Leitzmann MF, Rifai N, Kantoff PW, Chen YC, Stampfer MJ, Willett WC, Giovannucci E.

Cancer Epidemiol Biomarkers Prev. 2005 May;14(5):1262-9.

16.

Effect of a nutritional supplement containing vitamin E, selenium, vitamin c and coenzyme Q10 on serum PSA in patients with hormonally untreated carcinoma of the prostate: a randomised placebo-controlled study.

Hoenjet KM, Dagnelie PC, Delaere KP, Wijckmans NE, Zambon JV, Oosterhof GO.

Eur Urol. 2005 Apr;47(4):433-9; discussion 439-40. Epub 2005 Jan 19.

PMID:
15774238
17.

Dutasteride monotherapy in men with serologic relapse following radical therapy for adenocarcinoma of the prostate: a pilot study.

Perrotti M, Jain R, Abriel LM, Baroni TE, Corbett AB, Tenenbaum SA.

Urol Oncol. 2012 Mar-Apr;30(2):133-8. doi: 10.1016/j.urolonc.2010.01.004. Epub 2010 Aug 25.

PMID:
20800512
18.

Short-term androgen suppression and radiotherapy versus intermediate-term androgen suppression and radiotherapy, with or without zoledronic acid, in men with locally advanced prostate cancer (TROG 03.04 RADAR): an open-label, randomised, phase 3 factorial trial.

Denham JW, Joseph D, Lamb DS, Spry NA, Duchesne G, Matthews J, Atkinson C, Tai KH, Christie D, Kenny L, Turner S, Gogna NK, Diamond T, Delahunt B, Oldmeadow C, Attia J, Steigler A.

Lancet Oncol. 2014 Sep;15(10):1076-89. doi: 10.1016/S1470-2045(14)70328-6. Epub 2014 Aug 14.

PMID:
25130995
19.

A zero PSA slope in posttreatment prostate-specific antigen supports cure of patients with long-term follow-up after external beam radiotherapy for localized prostate cancer.

Takamiya R, Weinberg V, Young CD, Sandler H, McLaughlin P, Roach M 3rd.

Int J Radiat Oncol Biol Phys. 2003 Jul 15;56(4):1073-8.

PMID:
12829144
20.

Supplemental Content

Support Center